[Bone marrow autograft treated with mafosfamide in the acceleration phase in chronic myeloid leukemia. Inversion of the clinical development].
A 21-year old male patient with Philadelphia chromosome-positive chronic myeloid leukaemia received an autologous bone marrow transplant in consolidation of the 2nd chronic phase. The bone marrow had been treated with mafosfamide in adequate doses. The post-transplantation course of the disease was marked by an inversion: the duration of the 2nd chronic phase was more than 4 times longer than that of the first one, suggesting some degree of effectiveness of autologous bone marrow transplantation performed in the 2nd chronic phase and/for of the in vitro treatment of the bone marrow with mafosfamide. Cytogenetic monitoring was pursued throughout the course of leukaemia: regression of the Philadelphia chromosome was only partial and transient, and 3 clones appeared, each of them involving chromosome 1, for which mafosfamide was most probably responsible.
Fouillard
L
L
Service des Maladies du sang, Centre hospitalier universitaire Saint-Antoine, Paris.
Van Den Akker
J
J
Laporte
J P
JP
Najman
A
A
Perot
C
C
Lopez
M
M
Douay
L
L
Isnard
F
F
Taillemite
J L
JL
Gorin
N C
NC
D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects; D016026:Bone Marrow Transplantation; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000601:surgery*; D008297:Male; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; C048341:mafosfamide; D003520:Cyclophosphamide
Autogreffe de moelle osseuse traitée par mafosfamide en phase d'accélération de leucémie myéloïde chronique. Inversion de l'évolution clinique.